Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
Status:
Terminated
Trial end date:
2017-10-10
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1b/2 study is to evaluate the safety and tolerability of
PF-04136309 in combination with nab-paclitaxel and gemcitabine, characterize the
dose-limiting toxicities (DLTs) and overall safety profile of escalated doses of PF-04136309
and the associated schedule, determine the maximum tolerated dose (MTD), and to assess the
enhancement of efficacy of PF-04136309 in combination with nab-paclitaxel and gemcitabine
versus nab-paclitaxel + gemcitabine + placebo in terms of Progression Free Survival.